Third dose study
cancer
CANCER
We recruited patients via an informed consent process. Patients were required to be >18 years of age and have a cancer diagnosis either on active treatment or requiring active surveillance. Patients were also required to have received two doses of the mRNA COVID-19 vaccine or one dose of the adenoviral vaccine prior to enrollment. After drawing baseline labs that included spike antibody, a sample for T-cell assay, and a biobank sample, patients received a third mRNA vaccine (initially BNT162b2 per protocol, which was later amended to allow for third mRNA-1273 vaccine after the Food and Drug Administration [FDA] authorized ‘booster’ doses in fall of 2021). Patients who had received Ad26.CoV2.S vaccine received a BNT162b2 vaccine. The patients then returned for follow-up 4 weeks and 4–6 months after their third dose and their labs were repeated (